A man named Jim Cramer talked about a company called RxSight that makes things for eyes. He said it is too risky to buy, but the price of their shares went up a lot in one month. Other companies he mentioned also had changes in their prices. Some people think Tetra Tech and U.S. Silica are good to buy, while others don't like RxSight because they lose too much money. Read from source...

1. The title of the article is misleading and sensationalist. It implies that Jim Cramer has a negative opinion on RxSight, but in reality, he only said it was "too risky" and did not recommend it. However, the stock price still jumped 64% over the past month, which shows investors are ignoring his advice or seeing potential in the company despite the risk.
2. The article mentions Jim Cramer's opinion on Tetra Tech, but does not provide any context or explanation for why he said "I will bless it". This makes it seem like he randomly blessed the company without any reason, which is confusing and uninformative for readers.
3. The article discusses RxSight's preliminary revenue guidance above estimates, but does not mention how much higher it is or what the actual estimates were. This information would be useful for readers to understand the magnitude of the company's performance and whether it is a sustainable trend or a one-time event.
4. The article compares RxSight's stock price with that of other companies, such as U.S. Silica and Praxis Precision Medicine, but does not explain why these comparisons are relevant or what they imply for RxSight's future prospects. For example, it would be helpful to know if the companies have similar business models, target markets, or competitive advantages.
5. The article ends with a reference to another article about Tesla, American Airlines, and three other stocks to watch heading into the fourth quarter. This seems like an irrelevant and abrupt switch in topic, as it has nothing to do with healthcare or Jim Cramer's opinions. It also does not provide any context or connection between the two articles, leaving readers wondering why they are mentioned together.

I have carefully analyzed the article you provided and I have identified some potential investment opportunities for you based on the information given. Please note that these are only suggestions and not guarantees of success, as there are always inherent risks involved in any investment decision. You should do your own research and consult with a professional financial advisor before making any decisions. Here are my recommendations:

1. RXSight (NASDAQ:RXST) - This is a healthcare stock that has been performing well recently, despite Jim Cramer's negative opinion of it. The company issued positive revenue guidance and received a price target increase from Needham, which indicates a strong potential for growth. However, this also means that the stock might be overvalued or close to its peak, so you should consider selling some of your shares if you have made significant profits. The main risk factor for RXSight is its high debt level, which could limit its financial flexibility and hinder its ability to expand its operations or invest in research and development.
2. Praxis Precision Medicine (NASDAQ:PRAX) - This is another healthcare stock that has shown impressive gains over the past month, despite Jim Cramer's warning of its riskiness. The company is focused on developing personalized cancer therapies based on the genetic profile of each patient, which could make it a leader in the emerging field of precision medicine. However, this also means that the stock is highly speculative and volatile, as there are many uncertainties and challenges involved in bringing new drugs to market and gaining regulatory approval. The main risk factor for Praxis Precision Medicine is its lack of revenue and negative cash flow, which could indicate a poor business model or unsustainable spending habits.